As such, in vitro and in vivo blockade of PD-L1 and PD-L2 by sPD-1 delivered via gene therapy was shown to enhance tumor-specific T cell responses resulting in suppression of tumor growth (161–164). The gene discussed is HOXD13; the disease is neoplasm.